Corvus Pharmaceuticals Inc (NASDAQ:CRVS) shares, rose in value on Friday, March 28, with the stock price up by 0.30% to the previous day’s close as strong demand from buyers drove the stock to $3.38.
Actively observing the price movement in the last trading, the stock closed the session at $3.37, falling within a range of $3.23 and $3.445. Referring to stock’s 52-week performance, its high was $10.00, and the low was $1.30. On the whole, CRVS has fluctuated by -14.21% over the past month.
With the market capitalization of Corvus Pharmaceuticals Inc currently standing at about $230.30 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-24.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRVS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of CRVS currently trading nearly -19.50% and -26.58% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 30.58, while the 7-day volatility ratio is showing 13.72% which for the 30-day chart, stands at 9.41%. Furthermore, Corvus Pharmaceuticals Inc (CRVS)’s beta value is 0.66, and its average true range (ATR) is 0.37.
A comparison of Corvus Pharmaceuticals Inc (CRVS) with its peers suggests the former has fared considerably weaker in the market. CRVS showed an intraday change of 0.30% in last session, and over the past year, it grew by 92.05%%.
Data on historical trading for Corvus Pharmaceuticals Inc (NASDAQ:CRVS) indicates that the trading volumes over the past 10 days have averaged 0.8 and over the past 3 months, they’ve averaged 600.57K. According to company’s latest data on outstanding shares, there are 67.90 million shares outstanding.
Nearly 26.84% of Corvus Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 34.09% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.39 million shares as on 2025-03-14, resulting in a short ratio of 8.39. According to the data, the short interest in Corvus Pharmaceuticals Inc (CRVS) stood at 1034.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 5.73 million. The stock has fallen by -36.82% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRVS stock heading into the next quarter.
